Evelyn Marie Gutiérrez Rico

Evelyn Marie Gutiérrez Rico

Auto-generated profile, based on publicly available information

Evelyn Marie Gutiérrez Rico

Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
TSTakahiro Saito
Takahiro Saito
EREvelyn Marie Gutiérrez Rico
Evelyn Marie Gutiérrez Rico
AKAoi Kikuchi
Aoi Kikuchi
AKAkira Kaneko
Akira Kaneko
MKMasaki Kumondai
Masaki Kumondai
Masahiro HiratsukaMasahiro Hiratsuka
Masahiro Hiratsuka

1 October 2018 in Biochemical Pharmacology
Verified
Journal Article
Closed access
TWTakashi Watanabe
Takashi Watanabe
TSTakahiro Saito
Takahiro Saito
EREvelyn Marie Gutiérrez Rico
Evelyn Marie Gutiérrez Rico
EHEiji Hishinuma
Eiji Hishinuma
MKMasaki Kumondai
Masaki Kumondai
Masahiro HiratsukaMasahiro Hiratsuka
Masahiro Hiratsuka

Verified
Journal Article
Open access
PDF file
EHEiji Hishinuma
Eiji Hishinuma
EREvelyn Gutiérrez Rico
Evelyn Gutiérrez Rico
Masahiro HiratsukaMasahiro Hiratsuka
Masahiro Hiratsuka
Fluoropyrimidine drugs (FPs), including 5-fluorouracil, tegafur, capecitabine, and doxifluridine, are among the most widely used anticancer agents in the treatment of solid tumors. However, severe toxicity occurs in approximately 30% of patients following FP administration, emphasizing the importance of predicting the risk of acute toxicity before treatment. Three metabolic enzymes, dihydropyrimidine dehydrogenase (DPD), dihydropyrimidinase (DHP), and β-ureidopropionase (β-UP), degrade FPs; hence, deficiencies in these enzymes, arising from genetic polymorphisms, are involved in severe FP-related toxicity, although the effect of these polymorphisms on in vivo enzymatic activity has not been clarified. Furthermore, the clinical usefulness of current methods for predicting in vivo activity, such as pyrimidine concentrations in blood or urine, is unknown. In vitro tests have been established as advantageous for predicting the in vivo activity of enzyme variants. This is due to several studies that evaluated FP activities after enzyme metabolism using transient expression systems in Escherichia coli or mammalian cells; however, there are no comparative reports of these results. Thus, in this review, we summarized the results of in vitro analyses involving DPD, DHP, and β-UP in an attempt to encourage further comparative studies using these drug types and to aid in the elucidation of their underlying mechanisms.

1 February 2020 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
EREvelyn Marie Gutiérrez Rico
Evelyn Marie Gutiérrez Rico
AKAoi Kikuchi
Aoi Kikuchi
TSTakahiro Saito
Takahiro Saito
MKMasaki Kumondai
Masaki Kumondai
EHEiji Hishinuma
Eiji Hishinuma
Masahiro HiratsukaMasahiro Hiratsuka
Masahiro Hiratsuka

9 May 2017 in Journal of Natural Medicines
Verified
Journal Article
Closed access
PDF file
Ichiro KawahataIchiro Kawahata
Ichiro Kawahata
TSTatsuya Suzuki
Tatsuya Suzuki
EREvelyn Gutiérrez Rico
Evelyn Gutiérrez Rico
SKShuichi Kusano
Shuichi Kusano
HTHiroshi Tamura
Hiroshi Tamura
TYTohru Yamakuni
Tohru Yamakuni

10 July 2024 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Open access
KMKelvin Musyoka
Kelvin Musyoka
CCChim W. Chan
Chim W. Chan
EREvelyn Marie Gutiérrez Rico
Evelyn Marie Gutiérrez Rico
POProtus Omondi
Protus Omondi
CKCaroline Kijogi
Caroline Kijogi
AKAkira Kaneko
Akira Kaneko
Cytochrome P450 3A4 (CYP3A4) enzyme is involved in the metabolism of about 30 % of clinically used drugs, including the antimalarials artemether and lumefantrine. CYP3A4 polymorphisms yield enzymatic variants that contribute to inter-individual variation in drug metabolism. Here, we examined CYP3A4 polymorphisms in populations from malaria-endemic islands in Lake Victoria, Kenya, and Vanuatu, to expand on the limited data sets. We used archived dried blood spots collected from 142 Kenyan and 263 ni-Vanuatu adults during cross-sectional malaria surveys in 2013 and 2005-13, respectively, to detect CYP3A4 variation by polymerase chain reaction (PCR) and sequencing. In Kenya, we identified 14 CYP3A4 single nucleotide polymorphisms (SNPs), including the 4713G (CYP3A4∗1B; allele frequency 83.9 %) and 19382A (CYP3A4∗15; 0.7 %) variants that were previously linked to altered metabolism of antimalarials. In Vanuatu, we detected 15 SNPs, including the 4713A (CYP3A4∗1A; 88.6 %) and 25183C (CYP3A4∗18; 0.6 %) variants. Additionally, we detected a rare and novel SNP C4614T (0.8 %) in the 5' untranslated region. A higher proportion of CYP3A4 genetic variance was found among ni-Vanuatu populations (16 %) than among Lake Victoria Kenyan populations (8 %). Our work augments the scarce data sets and contributes to improved precision medicine approaches, particularly to anti-malarial chemotherapy, in East African and Pacific Islander populations.